Optinose Welcomes Terry Kohler as Chief Financial Officer
Optinose, a leading pharmaceutical company specializing in ear, nose, and throat (ENT) treatments, has taken a significant step forward by appointing Terry Kohler as its new Chief Financial Officer. Kohler's extensive background in biotechnology finance positions him to help steer Optinose towards its ambitious growth objectives.
Mr. Kohler's Previous Experience
Terry Kohler brings over two decades of financial leadership to Optinose, most recently serving as the Chief Financial Officer at Verrica Pharmaceuticals. In this role, he played a pivotal part in preparing the company for the launch of a novel topical treatment and enhancing their research and development efforts. His expertise will be instrumental in guiding Optinose as it expands its market offerings.
Leadership Insights
According to CEO Ramy Mahmoud, MD, MPH, the addition of Kohler to the leadership team is a strategic move to enhance the company’s financial strategy. Mahmoud expressed enthusiasm about Kohler’s expertise in navigating the commercial landscape of branded pharmaceuticals, particularly as it relates to XHANCE, a product designed for chronic rhinosinusitis treatment.
Kohler's Vision for Optinose
Kohler has described the opportunity to join Optinose as exciting, particularly at a time when XHANCE is moving toward new indications that promise substantial growth potential. He highlighted the significant market opportunity for chronic sinusitis treatments, believing that various strategic paths lie ahead for the company.
Compensation Structure and Benefits
In connection with his new role, Kohler will receive an inducement award comprising a non-qualified stock option to purchase up to 675,000 shares of common stock and 150,000 restricted stock units. The pricing of the stock options reflects the market value on his appointment date and underscores Optinose's commitment to rewarding its key executives appropriately for their contributions toward corporate success.
About Optinose
Optinose is devoted to improving the lives of patients with ENT and allergy conditions. It specializes in delivering innovative solutions, particularly through its flagship product, XHANCE, which utilizes a unique delivery system for treating chronic sinusitis.
XHANCE: A Breakthrough Treatment
XHANCE (fluticasone propionate) nasal spray is recognized for its effectiveness in treating chronic rhinosinusitis, both with and without nasal polyps. Its advanced delivery mechanism ensures that medication reaches critical areas within the nasal cavity, providing optimal therapeutic benefits for patients aged 18 and over.
Company Contacts
For further inquiries, investors can reach out to Jonathan Neely at Optinose at 267.521.0531 or via email at jonathan.neely@optinose.com. The company encourages communication to foster stronger investor relations and engagement in their strategic endeavors.
Frequently Asked Questions
What is the role of the Chief Financial Officer at Optinose?
The CFO is responsible for overseeing the financial operations of the company, including financial strategy, reporting, and guiding investments for growth.
Why is Terry Kohler's appointment significant?
Kohler's extensive finance experience in the biotech sector positions him to enhance Optinose's ability to execute its business model effectively, particularly in maximizing the value of XHANCE.
What is XHANCE used for?
XHANCE is a nasal spray approved for treating chronic rhinosinusitis, an inflammatory condition affecting the sinuses and nasal passages.
How does XHANCE work?
This treatment uses a specialized delivery system to ensure medication reaches the deeper regions of the nasal cavity, providing effective relief.
Who can I contact for more information about Optinose?
Investors can contact Jonathan Neely at 267.521.0531 or through email at jonathan.neely@optinose.com for further inquiries.
